^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR positive

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    6d
    Pangeia-2: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative • HER-2 mutation • PTEN mutation • PGR positive
    7d
    Sociodemographic Profile, Reproductive Factors and Presentation Pattern in Breast Cancer Patients from North India: A Hospital Based Study. (PubMed, J Pharm Bioallied Sci)
    Breast cancer in North India affects women at younger age with advanced stage presentation. Awareness, early diagnosis and improving access to care are needed to reduce disease burden.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • PGR positive
    9d
    RADIOLA: Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (clinicaltrials.gov)
    P2, N=65, Completed, SOLTI Breast Cancer Research Group | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • HER-2 negative + AR positive + ER positive
    |
    Lynparza (olaparib)
    11d
    Study of 68Ga-R10602 (clinicaltrials.gov)
    P1, N=36, Recruiting, Radionetics Oncology | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    13d
    Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruth O'Regan | Trial completion date: Jan 2026 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole
    16d
    Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    19d
    Rare manifestation of paclitaxel-induced cardiotoxicity: A case of restrictive cardiomyopathy in an elderly breast cancer patient. (PubMed, Indian J Pharmacol)
    Prompt cessation of paclitaxel and initiation of heart failure therapy led to clinical improvement. This case highlights the need for vigilance for cardiac toxicities in chemotherapy patients with cardio-oncology collaboration.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    paclitaxel
    21d
    LUBRECA: Luminal Breast Cancer Cryoablation (clinicaltrials.gov)
    P=N/A, N=140, Recruiting, Lucía Graña López
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    22d
    Fulvestrant With or Without Ganetespib in HR+ Breast Cancer (clinicaltrials.gov)
    P2, N=50, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    fulvestrant • ganetespib (ADX-1612)
    25d
    Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov)
    P=N/A, N=3883, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    PGR positive • EGFR negative
    |
    Verzenio (abemaciclib) • letrozole • anastrozole
    26d
    Occult metastasis of hormone receptor-positive breast cancer to the ovary: A case report and literature review. (PubMed, Medicine (Baltimore))
    This case highlights the distinct characteristics of ovarian metastases in HR+/HER2- breast cancer and their critical importance in differential diagnosis, particularly in distinguishing them from primary gynecologic tumors. For patients with a history of breast cancer, the presence of pelvic lesions should prompt consideration of metastatic potential to guide appropriate comprehensive treatment.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • PGR positive • EGFR positive
    |
    docetaxel • doxorubicin hydrochloride • cyclophosphamide
    28d
    CLEE011O12001: A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. (2022-503001-38-01)
    P2/3, N=172, Active, not recruiting, Novartis Pharma AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension